Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01055106|
Recruitment Status : Completed
First Posted : January 25, 2010
Last Update Posted : July 1, 2011
|Condition or disease||Intervention/treatment||Phase|
|Vaginosis, Bacterial Vaginal Infection||Drug: GW05 Drug: Metronidazole||Phase 2|
This is a multicenter, randomized, investigator-blinded, phase 2, dose ranging study of GW05 vaginal gel administered in 3 regimens compared to metronidazole 0.75% (QD x 5 days) for the treatment of bacterial vaginosis. Subjects will be evaluated at three timepoints (1 screening/baseline visit, post-treatment phone call and 1 test-of-cure visit). The total study duration may be up to 30 days for a subject.
Study medication will be applied intravaginally once daily at bedtime according to the assigned dosing schedule using the supplied 5-gram vaginal applicators.
Investigator blinding will be ensured by utilizing an independent drug dispensing coordinator at each site.
Bacterial vaginosis (BV) is an infection of the vagina (birth canal) that is the result of an overgrowth of bacteria that are often normally found in the vagina. This type of vaginal infection typically does not cause irritation. The most common complaint of patients who suffer from BV is a fishy-smelling vaginal discharge. The amount of vaginal discharge may or may not be increased above a normal discharge. The bad odor may get worse after sexual intercourse or during the menstrual period. BV is also strongly associated with problems during pregnancy, such as premature (early) birth, and with an increased risk of sexually transmitted diseases. Therefore, it is important to treat the infection.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||255 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||April 2010|
|Actual Study Completion Date :||April 2010|
|Active Comparator: 1D||
vaginal gel once daily regimen A
|Active Comparator: 3D||
vaginal gel once daily regimen B
|Active Comparator: 5D||
vaginal gel once daily regimen C
|Active Comparator: Metronidazole||
vaginal gel 0.75% once daily for 5 days
- proportion of subjects with therapeutic cure [ Time Frame: day 21 to day 30 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01055106
|Study Director:||Sharon F Levy, MD||Graceway Pharmaceuticals|